Loading
DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
Involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively. Core component of the UV-DDB complex (UV-damaged DNA-binding protein complex), a complex that recognises UV-induced DNA damage and recruits proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. The UV-DDB complex preferentially binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4 PP), apurinic sites and short mismatches.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.89, genetic association 0.00, clinical 0.99).
In plain words · DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
Involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively.
No product in this corpus aims at DDB1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists DDB1 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA DDB1: RNA low tissue specificity; high antibody staining in 16 normal tissues; highest cancer staining melanoma (4 of 11 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma, Myeloid neoplasms); Open Targets associates it with 4 specific cancer types at or above 0.5 (plasma cell myeloma, follicular lymphoma, myelodysplastic syndrome, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas DDB1 tissue; Open Targets ENSG00000167986 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Dualan et al, Genomics, 1995, "Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein". Source.
Sources: HGNC HGNC:2717 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q16531 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000167986 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.59, myelodysplastic syndrome 0.56, follicular lymphoma 0.57, mantle cell lymphoma 0.55 (GraphQL API, CC0))
Involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively. Core component of the UV-DDB complex (UV-damaged DNA-binding protein complex), a complex that recognises UV-induced DNA damage and recruits proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. The UV-DDB complex preferentially binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4 PP), apurinic sites and short mismatches. Component of numerous distinct DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. The functional specificity of the DCX E3 ubiquitin-protein ligase complex is determined by the variable substrate recognition component recruited by DDB1. DCX(DDB2) (also known as DDB1-CUL4-ROC1, CUL4-DDB-ROC1 and CUL4-DDB-RBX1) may ubiquitinate histone H2A, histone H3 and histone H4 at sites of UV-induced DNA damage. Location: Cytoplasm; Nucleus (UniProt). Locus 11q12.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Bone marrow, Bronchus, Cervix, Duodenum, Endometrium, Fallopian tube, Liver, Lung.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA DDB1 tissue · HPA DDB1 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DDB1" OR ABSTRACT:"DDB1" OR TITLE:"damage specific DNA binding protein 1" OR ABSTRACT:"damage specific DNA binding protein 1" OR TITLE:"DNA damage-binding protein 1" OR ABSTRACT:"DNA damage-binding protein 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DDB1, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.